Regulated drug bioanalysis for human pharmacokinetic studies and therapeutic drug management

Bioanalysis

Volumn 4, Issue 15, 2012, Pages 1919-1931

  Huang, Yong ^a   Shi, Robert ^a   Gee, Winnie ^a   Bonderud, Richard ^a  

^a University of California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; BLUNDER; CODING AND CLASSIFICATION; CONTROLLED STUDY; DRUG ANALYSIS; DRUG BIOANALYSIS; DRUG MONITORING; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HUMAN; INTERMETHOD COMPARISON; NOMENCLATURE; PRACTICE GUIDELINE; RANDOM ERROR; REVIEW; SAMPLE; SYSTEMATIC ERROR; THERAPEUTIC DRUG MANAGEMENT; UNITED STATES; VALIDATION PROCESS;

ANIMALS; CALIBRATION; CHEMISTRY TECHNIQUES, ANALYTICAL; EUROPE; GUIDELINES AS TOPIC; HUMANS; LABORATORIES; ORGANIZATIONS, NONPROFIT; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THERAPEUTIC EQUIVALENCY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84865768355     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.12.157     Document Type: Review

References (69)

1. Hill HM. Development of bioanalysis: A short history. Bioanalysis 1(1), 3-7 (2009
2. Ezzelle J, Rodriguez-Chavez IR, Darden JM et al. Guidelines on good clinical laboratory practice: Bridging operations between research and clinical research laboratories. J. Pharm. Biomed. Anal. 46(1), 18-29 (2008 (Pubitemid 350216340)
3. Shah VP, Midha KK, Findlay JW et al. Bioanalytical method validation - a revisit with a decade of progress. Pharm. Res. 17(12), 1551-1557 (2000 (Pubitemid 32217566)
4. Shah VP, Bansal S. Historical perspective on the development and evolution of bioanalytical guidance and technology. Bioanalysis 3(8), 823-827 (2011
5. Viswanathan CT, Bansal S, Booth B et al. Workshop/conference report - quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays. AAPS J. 9(1), E30-E42 (2007). Updated and clarified many regulated drug bioanalysis issues. (Pubitemid 46296546)
6. Fast DM, Kelley M, Viswanathan CT et al. Workshop report and follow-up - AAPS workshop on current topics in GLP bioanalysis: Assay reproducibility for incurred samples - implications of Crystal City Recommendations. AAPS J. 11(2), 238-241 (2009
7. van Amsterdam P, Arnold M, Bansal S et al. Building the global bioanalysis consortium - working towards a functional globally acceptable and harmonized guideline on bioanalytical method validation. Bioanalysis 2(11), 1801-1803 (2010
8. Bansal SK, Arnold M, Garofolo F. International harmonization of bioanalytical guidance. Bioanalysis 2(4), 685-687 (2010
9. Garofolo F, Michon J, Leclaire V et al. US FDA/EMA harmonization of their bioanalytical guidance/guideline and activities of the Global Bioanalytical Consortium. Bioanalysis 4(3), 231-236 (2012
10. Hammett-Stabler CA, Garg U. The evolution of mass spectrometry in the clinical laboratory. Methods Mol. Biol. 603, 1-7 (2010
11. Lasky FD, Kroll MH, Tholen DW. Evaluation of Matrix Effects; Approved Guideline - Second Edition. Clinical and Laboratory Standards Institute 25(4), EP14-A2 (2005
12. McEnroe RJ, Burritt MF, Powers DM, Rheinheimer DW, Wallace BH. Interference Testing in Clinical Chemistry; Approved Guideline - Second Edition. Clinical and Laboratory Standards Institute 25(27), EP7-A2 (2005
13. ISO 5. 5725-5721 Accuracy (Trueness and Precision) of Measurement Methods and Results, Part 1: General Principles and Definitions. Geneva, Switzerland: ISO; 1994.
14. Thompson M, Ellison SLR, Wood R. Harmonized guidelines for single-laboratory validation of methods of analysis (IUPAC Technical Report). Pure Appl. Chem. 74(5), 835-855 (2002). A harmonized guidance for a general method validation (International Union of Pure and Applied Chemistry, International Organization for Standardization and International Association of Official Analytical Chemists
15. James CA, Breda M, Frigerio E. Bioanalytical method validation: A risk-based approach? J. Pharm. Biomed. Anal. 35(4), 887-893 (2004 (Pubitemid 38757679)
16. Vessman J, Stefan RI, Van Staden JF et al. Selectivity in analytical chemistry. Pure Appl. Chem. 73, 1381-1386 (2001
17. Persson BA, Vessman J. The use of selectivity in analytical chemistry - some considerations. Trends Anal. Chem. 20, 526-532 (2001 (Pubitemid 33000322)
18. Karnes HT, Shiu G, Shah VP. Validation of bioanalytical methods. Pharm. Res. 8(4), 421-426 (1991). Early conceptual paper for bioanalytical method validation.
19. Aboul-Enein AH. Selectivity versus specificity in chromatographic analytical methods. Accred. Qual. Assur. 5, 180-181 (2000
20. Rozet E, Ceccato A, Hubert C et al. Analysis of recent pharmaceutical regulatory documents on analytical method validation. J. Chromatogr. A 1158(1-2), 111-125 (2007 (Pubitemid 47028571)
21. Huang Y, Shi R, Gee W, Bonderud R. Matrix effect and recovery terminology issues in regulated drug bioanalysis. Bioanalysis 4(3), 271-279 (2012
22. Westgard JO. In: Basic Method Validation. 3rd Edition. Westgard QC, Inc., WI, USA (2008). Key book of basic method validation for the clinical laboratory.
23. Taylor JK. Quality Assurance of Chemical Measurements. Lewis Publishers, MI, USA (1987
24. Savoie N, Garofolo F, van Amsterdam P et al. 2009 White Paper on recent issues in regulated bioanalysis from the 3rd Calibration and Validation Group Workshop. Bioanalysis 2(1), 53-68 (2010
25. Savoie N, Booth BP, Bradley T et al. The 2nd Calibration and Validation Group workshop on recent issues in good laboratory practice bioanalysis. Bioanalysis 1(1), 19-30 (2009
26. Kellermeyer RW, Tarlov AR, Brewer GJ, Carson PE, Alving AS. Hemolytic effect of therapeutic drugs. Clinical considerations of the primaquine-type hemolysis. JAMA 180, 388-394 (1962
27. Sonntag O. Haemolysis as an interference factor in clinical chemistry. J. Clin. Chem. Clin. Biochem. 24(2), 127-139 (1986 (Pubitemid 16105580)
28. Carraro P. Hemolyzed Specimens: A reason for rejection or a clinical challenge? Clin. Chem. 46, 306-307 (2000 (Pubitemid 30104266)
29. Lippi G, Blanckaert N, Bonini P et al. Haemolysis: An overview of the leading cause of unsuitable specimens in clinical laboratories. Clin. Chem. Lab. Med. 46(6), 764-772 (2008 (Pubitemid 351821645)
30. Kringle RO. An assessment of the 4-6-20 rule for acceptance of analytical runs in bioavailability, bioequivalence, and pharmacokinetic studies. Pharm. Res. 11, 556-560 (1994 (Pubitemid 24144449)
31. Hartmann C, Massart DL, McDowall RD. An analysis of the Washington Conference Report on bioanalytical method validation. J. Pharm. Biomed. Anal. 12, 1337-1343 (1994 (Pubitemid 24339384)
32. Boulanger B, Rozet E, Moonen F, Rudaz S, Hubert P. A risk-based analysis of the AAPS conference report on quantitative bioanalytical methods validation and implementation. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877(23), 2235-2243 (2009
33. Hoffman D, Kringle R. A total error approach for the validation of quantitative analytical methods. Pharm. Res. 24(6), 1157-1164 (2007 (Pubitemid 46798895)
34. Bansal S, DeStefano A. Key elements of bioanalytical method validation for small molecules. AAPS J. 9(1), E109-E114 (2007
35. Meng M, Reuschel S, Bennett P. Identifying trends and developing solutions for incurred sample reanalysis failure investigations in a bioanalytical CRO. Bioanalysis 3(4), 449-465 (2011
36. Yadav M, Shrivastav PS. Incurred sample reanalysis (ISR): A decisive tool in bioanalytical research. Bioanalysis 3(9), 1007-1024 (2011
37. Levey S, Jennings ER. The use of control charts in the clinical laboratory. Am. J. Clin. Pathol. 20(11), 1059-1066 (1950
38. Westgard JO, Barry PL, Hunt MR, Groth T. A multi-rule Shewhart chart for quality control in clinical chemistry. Clin. Chem. 27(3), 493-501 (1981
39. Jenny RW, Jackson KY. Evaluation of the rigor and appropriateness of CLIA '88 toxicology proficiency testing standards. Clin. Chem. 38(4), 496-500 (1992
40. van Luin M, Wit FW, Smit C et al. Adherence to HIV therapeutic drug monitoring guidelines in The Netherlands. Ther. Drug Monit. 33(1), 32-39 (2011
41. Holland DT, DiFrancesco R, Connor JD, Morse GD. Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: A requirement for therapeutic drug monitoring. Ther. Drug Monit. 28(3), 367-374 (2006 (Pubitemid 44314924)
42. Lee JW, Devanarayan V, Barrett YC et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23(2), 312-328 (2006). Comprehensive review of biomarker method validation for drug development. (Pubitemid 43237862)
43. Steele BW, Wang E, Palomaki GE et al. An evaluation of analytic goals for assays of drugs: A College of American Pathologists Therapeutic Drug Monitoring Survey Study. Arch. Pathol. Lab. Med. 125(6), 729-735 (2001 (Pubitemid 32520514)
44. Bowers LD. Analytical goals in therapeutic drug monitoring. Clin. Chem. 44(2), 375-380 (1998 (Pubitemid 28087744)
45. Hammett-Stabler CA, Johns T. Laboratory guidelines for monitoring of antimicrobial drugs. National Academy of Clinical Biochemistry. Clin. Chem. 44(5), 1129-1140 (1998 (Pubitemid 28213161)
46. Shaw LM, Nicholls A, Hale M et al. Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin. Biochem. 31(5), 317-322 (1998 (Pubitemid 28385228)
47. Garofolo F, Rocci ML Jr, Dumont I et al. 2011 White paper on recent issues in bioanalysis and regulatory findings from audits and inspections. Bioanalysis 3(18), 2081-2096 (2011
48. Peck C. The randomized concentration-controlled clinical trial (CCT): An information-rich alternative to the randomized placebo controlled clinical trial (PCT). Clin. Pharmacol. Ther. 47, 148 (1990
49. Fletcher CV, Acosta EP, Henry K et al. Concentration-controlled zidovudine therapy. Clin. Pharmacol. Ther. 64, 331-338 (1998 (Pubitemid 28462294)
50. Evans WE, Relling MV, Rodman JH et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N. Engl. J. Med. 338, 499-505 (1998 (Pubitemid 28103133)
51. Kraiczi H, Jang T, Ludden T, Peck CC. Randomized concentration-controlled trials: Motivations, use, and limitations. Clin. Pharmacol. Ther. 74(3), 203-214 (2003 (Pubitemid 37083096)
52. Baboolal K. A Phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Transplantation 75(8), 1404-1408 (2003 (Pubitemid 36513057)
53. van Gelder T, Hilbrands LB, Vanrenterghem Y et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 68, 261-266 (1999 (Pubitemid 29360288)
54. Edelbroek PM, van der Heijden J, Stolk LM. Dried blood spot methods in therapeutic drug monitoring: Methods, assays, and pitfalls. Ther. Drug Monit. 31(3), 327-336 (2009
55. Mullangi R, Agrawal S, Srinivas NR. Measurement of xenobiotics in saliva: Is saliva an attractive alternative matrix? Case studies and analytical perspectives. Biomed. Chromatogr. 23(1), 3-25 (2009
56. Capron A, Musuamba F, Latinne D et al. Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in peripheral blood mononuclear cells. Ther. Drug Monit. 31(2), 178-186 (2009
57. Müller DM, Rentsch KM. Therapeutic drug monitoring by LC-MS/MS with special focus on anti-infective drugs. Anal. Bioanal. Chem. 398(6), 2573-2594 (2010
58. Beumer JH, Bosman IJ, Maes RA. Hair as a biological specimen for therapeutic drug monitoring. Int. J. Clin. Pract. 55(6), 353-357 (2001 (Pubitemid 32707640)
59. Uematsu T. Therapeutic drug monitoring in hair samples. Principles and practice. Clin. Pharmacokinet. 25(2), 83-87 (1993 (Pubitemid 23232388)
60. Huang Y, Gandhi M, Greenblatt RM, Gee W, Lin ET, Massenkoff N. Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun. Mass Spectrom. 22(21), 3401-3409 (2008
61. Huang Y, Yang Q, Yoon K et al. Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry. Anal. Bioanal. Chem. 401(6), 1923-1933 (2011
62. Handy R, Trepanier D, Scott G, Foster R, Freitag D. Development and validation of a LC-MS/MS method for quantifying the next generation calcineurin inhibitor, voclosporin, in human whole blood. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 874(1-2), 57-63 (2008
63. Keil K, Hochreitter J, DiFrancesco R et al. Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: Validation and application. Ther. Drug Monit. 29(1), 103-109 (2007 (Pubitemid 46279883)
64. Boudennaia TY, Napoli KL. Validation of a practical liquid chomatography with ultraviolet detection method for quantification of whole-blood everolimus in a clinical TDM laboratory. Ther. Drug Monit. 27(2), 171-177 (2005 (Pubitemid 40463645)
65. Dybkaer R. Setting quality specifications for the future with newer approaches to defining uncertainty in laboratory medicine. Scand. J. Clin. Lab. Invest. 59(7), 579-583 (1999 (Pubitemid 30056756)
66. Feinberg M, Boulanger B, Dewé W, Hubert P. New advances in method validation and measurement uncertainty aimed at improving the quality of chemical data. Anal. Bioanal. Chem. 380(3), 502-514 (2004
67. Rozet E, Marini RD, Ziemons E, Boulanger B, Hubert P. Advances in validation, risk and uncertainty assessment of bioanalytical methods. J. Pharm. Biomed. Anal. 55(4), 848-858 (2011
68. Shah KA, Karnes HT. A proposed 'fixed' range decision criteria for transfer of bioanalytical methods. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877(23), 2270-2274 (2009
69. Hoffman D. Statistical considerations for assessment of bioanalytical incurred sample reproducibility. AAPS J. 11, 570-580 (2009).